


MOUNT SINAI LIVER
CANCER PROGRAM

15TH ANNIVERSARY

LIVE VIRTUAL ACTIVITY

LIVER CANCER:
*Advances in Science and
Clinical Management*

FRIDAY, DECEMBER 11, 2020



Program Director

Josep M. Llovet, MD, PhD

Co-Director, Mount Sinai Liver Cancer Program

Sponsored by

Mount Sinai Liver Cancer Program

Tisch Cancer Institute



**Mount
Sinai** *The Tisch Cancer Institute*


1st NCI recognized Liver Cancer Program in the U.S.

LIVER CANCER: Advances in Science and Clinical Management

FRIDAY, DECEMBER 11, 2020

PROGRAM

- 8:30 – 9:00am** **Registration**
- 9:00 – 9:10am** **Welcome and Opening**
Ramon Parsons, MD, PhD, Director, Tisch Cancer Institute
- 9:10 – 9:40am** **Achievements of Mount Sinai Liver Cancer Program 2005-20**
Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 9:40 – 10:20am** **Hans Popper Lecture**
Introduction: Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
Precision Medicine in Cholangiocarcinoma
Gregory Gores, MD, PhD, Mayo Clinic, Rochester, Minnesota
-
- 10:20 – 10:40am** **Coffee Break**
-
- 10:40 – 12:00pm** **PATHOGENESIS OF LIVER CANCER**
Chairman: Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
- 10:40 – 11:10am** **Overview: From Fibrosis to Liver Cancer**
Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
- 11:10 – 11:30am** **Linking Pathology with Molecular Types of HCC and iCCA**
Swan Thung, MD, Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program
- 11:30 – 12:00pm** **Rationale for Early Immunotherapy Treatment in HCC**
Miriam Merad, MD, PhD, Director Precision Immunology Institute, Department of Oncological Sciences, Department of Hematology and Medical Oncology
-
- 12:00 – 12:40pm** **Lunch**
-
- 12:40 – 1:40pm** **MANAGEMENT OF LIVER CANCER (EARLY-INTERMEDIATE STAGE)**
Chairman: Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 12:40 – 1:00pm** **Advances in the Resection and Transplantation for HCC and iCCA**
Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 1:00 – 1:20pm** **Chemoembolization (TACE) and Radioembolization (TARE) in HCC**
Edward Kim, MD, Department of Radiology, Department of Surgery, Mount Sinai Liver Cancer Program



1:20 – 1:40pm	SBRT for Early and Intermediate HCC. Where Do We Stand? Michael Buckstein, MD, PhD, Department of Radiation Oncology
1:40 – 2:00pm	Coffee Break
2:00 – 3:20pm	MANAGEMENT OF LIVER CANCER (ADVANCED STAGE) <i>Chairman:</i> Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
2:00 – 2:30pm	Molecular and Immune Therapies in Advanced HCC Josep M Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
2:30 – 2:50pm	New Emerging Therapies in Cancer and HCC- Phase I Studies Thomas Marron, MD, PhD, Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute
2:50 – 3:20pm	State-of-the-Art Lecture Implications of COVID-19 in the management of HCC: ILCA Guidelines Augusto Villanueva, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
3:20 – 3:40pm	Coffee Break
3:40 – 4:40pm	NOVEL TARGETS AND PRE-CLINICAL MODELS FOR LIVER CANCER TREATMENT <i>Chairman:</i> Samuel Waxman, MD, Mount Sinai Liver Cancer Program, Department of Hematology and Medical Oncology, Department of Oncological Sciences
3:40 – 4:00pm	New Perspective on the Molecular and Immune Classification of Intra and Extrahepatic cholangiocarcinoma Daniela Sia, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
4:00 – 4:20pm	Wnt Signaling and Immune Response, What We Know from Experimental Models Amaia Lujambio, PhD, Department of Oncological Sciences
4:20 – 4:40pm	Organoids and Other Patient-derived Preclinical Models of Liver Cancer Ernesto Guccione, PhD, Department of Oncological Sciences
4:40pm	Closing Remarks

Conference Information

<https://mssm.cloud-cme.com>

Office of CME at 212-731-7950 • e-mail: cme@mssm.edu



**Icahn School
of Medicine at
Mount
Sinai**

PROGRAM DIRECTOR

JOSEP M. LLOVET, MD, PhD

Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

PROGRAM CHAIRS

SCOTT FRIEDMAN, MD

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program,
Division of Liver Diseases

MYRON E. SCHWARTZ, MD

Mount Sinai Liver Cancer Program, Director of Liver Surgery,
Recanati/Miller Transplantation Institute

SAMUEL WAXMAN, MD

Professor of Medicine, Department of Hematology and Medical Oncology,
Department of Oncological Sciences

GUEST FACULTY

GREGORY GORES, MD, PhD

Executive Dean for Research, Mayo Clinic

HOST FACULTY

MICHAEL BUCKSTEIN, MD, PhD

Department of Radiation Oncology

SCOTT FRIEDMAN, MD

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program

ERNESTO GUCCIONE, PhD

Department of Oncological Sciences

EDWARD KIM, MD

Department of Radiology, Department of Surgery,
Mount Sinai Liver Cancer Program

JOSEP LLOVET, MD, PhD

Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

AMAIA LUJAMBIO, PhD

Department of Oncological Sciences

THOMAS MARRON, MD, PhD

Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute

MIRIAM MERAD, MD, PhD

Director Precision Immunology Institute, Department of Oncological Sciences,
Department of Hematology and Medical Oncology

RAMON PARSONS, MD, PhD

Director, Tisch Cancer Institute

MYRON SCHWARTZ, MD

Mount Sinai Liver Cancer Program, Director of Liver Surgery,
Recanati/Miller Transplantation Institute

DANIELA SIA, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

SWAN THUNG, MD

Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program

AUGUSTO VILLANUEVA, MD, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

SAMUEL WAXMAN, MD

Mount Sinai Liver Cancer Program, Department of Hematology and Medical Oncology,
Department of Oncological Sciences

Activity Learning Objectives

- Understand the epidemiology and disparities of liver cancer in the US.
- Review the current role of surgical and loco-regional treatments for liver cancer.
- Critical review of molecular therapies and SBRT in the management of advanced HCC
- Understand the molecular rationale for immune therapies in HCC.

Activity Description

This virtual activity will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and one outstanding invited lecturer. The meeting is intended to provide a summary of the state-of-the-art knowledge of the novel advancements reported in 2020 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

Target Audience

Hepatologists and Gastroenterologist, Oncologists, Surgeons, Radiologist, Pathologists and Basic Scientists interested in liver cancer from the New York Area and beyond.

Accreditation

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live internet activity for a maximum of 70 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Verification of Attendance

Verification of attendance will be provided to all professionals.

Special Needs

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations please contact the Page and William Black Post-Graduate School of Medicine at cme@mssm.edu.

Faculty Disclosure

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course materials.

Registration

<https://mssm.cloud-cme.com>

Registration Fee

Registration is complimentary

Acknowledgement

This activity is made possible in part by educational grants from:

Bristol-Myers Squibb, Celsion, Eisai, Inc., Merck & Co.

Icahn School of Medicine at Mount Sinai
The Page and William Black Post Graduate School
One Gustave L. Levy Place, Box 1193
New York, NY 10029-6574

**MOUNT SINAI LIVER
CANCER PROGRAM 15TH ANNIVERSARY**

***LIVER CANCER:
Advances in Science and
Clinical Management***



Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai

Complimentary Online Registration